These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 44567)

  • 1. [Fibrinolytic capacity after exertion in atherogenic hyperlipoproteinemias].
    Zdrenghea D; Mărcuşu C; Cucuianu M; Rentsch S
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1979; 31(5):435-40. PubMed ID: 44567
    [No Abstract]   [Full Text] [Related]  

  • 2. Behaviour of platelet adhesiveness and of dilute clot blood lysis time in hyperlipoproteinemic subjects.
    Zdrenghea D; Stef C; Cucuianu M; Vlaicu R
    Med Interne; 1979; 17(3):273-7. PubMed ID: 504931
    [No Abstract]   [Full Text] [Related]  

  • 3. [HDL, HDL2 and HDL3 cholesterol in various types of hyperlipoproteinemia in relation to clinical signs of arteriosclerosis].
    Sznajderman M; Zawadzki Z
    Kardiol Pol; 1986; 29(3):194-203. PubMed ID: 3773408
    [No Abstract]   [Full Text] [Related]  

  • 4. Hemorrheologic abnormalities in defined primary dyslipoproteinemias with both high and low atherosclerotic risks.
    Otto C; Ritter MM; Richter WO; Minkenberg R; Schwandt P
    Metabolism; 2001 Feb; 50(2):166-70. PubMed ID: 11229424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Beta 2 glycoprotein I analysis in patients with hyperlipoproteinemia, arteriosclerotic occlusive disease and diabetes mellitus].
    Müller G; Biering A; Lux E; Richter V
    Z Gesamte Inn Med; 1983 May; 38(10):282-4. PubMed ID: 6613192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison of the effects of fenofibrate administered in doses of 3 x 100mg and 1 x 250mg per day in patients with type IIA, IIB and IV hyperlipoproteinemias].
    Reiner Z; Salzer B; Kes P
    Acta Med Iugosl; 1988; 42(5):353-62. PubMed ID: 3245481
    [No Abstract]   [Full Text] [Related]  

  • 7. [Primary hyperlipoproteinemia in its clinical and laboratory aspects. IV. Blood coagulation and fibrinolysis indicators].
    Borodin M; Jurek D; Gregorczyk J; Pieczul-Mróz J; Cwajda H
    Przegl Lek; 1983; 40(10):727-32. PubMed ID: 6665208
    [No Abstract]   [Full Text] [Related]  

  • 8. Metabolism of plasma and biliary lipids in hyperlipoproteinaemia.
    Leijd B
    Acta Med Scand Suppl; 1979; 635():1-32. PubMed ID: 295570
    [No Abstract]   [Full Text] [Related]  

  • 9. [Study of phospholipids in primary hyperlipoproteinemias].
    Kuczyńska K
    Pol Arch Med Wewn; 1979 Jul; 62(1):29-40. PubMed ID: 503884
    [No Abstract]   [Full Text] [Related]  

  • 10. The effect of n-3 fatty acids on lipids and haemostasis in patients with type IIa and type IV hyperlipidaemia.
    Schmidt EB; Ernst E; Varming K; Pedersen JO; Dyerberg J
    Thromb Haemost; 1989 Sep; 62(2):797-801. PubMed ID: 2814927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Increase in the fibrinolytic activity in patients with hyperlipoproteinemias type IV treated with bezafibrate].
    Obispo TM; García Fradé LJ; García Avelló A; César J; Sastre A; Navarro JL
    Rev Clin Esp; 1988 Feb; 182(3):151-4. PubMed ID: 3368592
    [No Abstract]   [Full Text] [Related]  

  • 12. Increased in vitro platelet aggregation in hypertriglyceridemias.
    Riess H; Merk W; Falkner C; Hiller E
    Thromb Res; 1986 Feb; 41(3):281-9. PubMed ID: 3705010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of apoproteins A and B, lipoproteins and plasma lipids during treatment with bezafibrate in various forms of hyperlipoproteinemia].
    Saitta A; Bonaiuto M; Lanzafame F; Mileto A; Pernice F; Cinquegrani M; Mazza G; Micali G; Pangallo A; Fodale P
    Clin Ter; 1988 Mar; 124(5):373-81. PubMed ID: 2974348
    [No Abstract]   [Full Text] [Related]  

  • 14. [Subfractions of HDL cholesterol. Occurrence in hyperlipoproteinemia type IIa and IV].
    Mertz DP; Thuilot G; Bürvenich K
    Fortschr Med; 1986 Jul; 104(26):508-10. PubMed ID: 3744260
    [No Abstract]   [Full Text] [Related]  

  • 15. [Hyperlipoproteinemia, HDL-cholesterol and arteriosclerosis indices].
    Herrmann W; Reuter W
    Z Gesamte Inn Med; 1982 Dec; 37(24):830-3. PubMed ID: 6963524
    [No Abstract]   [Full Text] [Related]  

  • 16. [The clinico-biochemical activity and tolerance of the hypolipidemic preparation lipanthyl].
    Ol'binskaia LI; Vartanova OA; Aleksandrovskaia TN; Shaldaeva VV
    Ter Arkh; 1991; 63(8):61-4. PubMed ID: 1792621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Arzneimittelforschung; 1983; 33(5):776-9. PubMed ID: 6683558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic hyperlipidemia and atherosclerosis.
    Stone NJ
    Artery; 1979 May; 5(5):377-97. PubMed ID: 262162
    [No Abstract]   [Full Text] [Related]  

  • 19. [Composition of VLDL, LDL and HDL lipoprotein fractions in type IIa, IIb, III, IV, and V hyperlipemia patients in comparison with healthy individuals].
    Hutt V; Klör HU; Wechsler JG; Ditschuneit H
    J Clin Chem Clin Biochem; 1984 Feb; 22(2):141-6. PubMed ID: 6716054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [High-density lipoprotein cholesterol and the atherogenic index in patients with different types of hyperlipoproteinemias].
    Apostolov I; Naumova R; Balabanski L; Goranov I
    Vutr Boles; 1983; 22(3):70-4. PubMed ID: 6649586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.